Major Breakthrough in the Biosynthesis of Psilocybin, Psilocin and Related Tryptamine-based Compounds (Patreon)

Published:

2020-01-15 21:44:37

Imported:

2023-10

Content

It seems the psychedelic related breakthroughs just keep coming. CB Therapeutics is the latest to file a new patent that could lead to very efficient production of psilocybin and similar analogs which will help lower costs if psilocybin is ever approved by the FDA as medicine. That said, the real barrier as far as costs go will likely be the fact that all initial protocols for psilocybin treatment will require many hours of intensive supervision, preparation, and followup/integration time from a licensed/trained professional (psychiatrists or otherwise) - something that could prove cost prohibitive. It will be interesting to see what solutions develop to address that challenge. I wonder if there will ever be remote trip sitters or app assisted therapy and integration? My guess is that the underground self service model will grow after the FDA approves psilocybin for prescriptive use.

Files

CB Therapeutics Achieves Major Breakthrough in the Biosynthesis of Psilocybin, Psilocin and Related Tryptamine-based Compounds

SAN DIEGO--()--CB Therapeutics, Inc. has achieved the successful biosynthesis of psilocybin, psilocin and related tryptamine-based compounds typically found in plants and fungi and has filed a patent for the production process. In early testing, the analysis of raw analytical samples has shown the biosynthetic process to be significantly more efficient, of higher purity and less expensive than existing chemical and biosynthetic techniques or other production methods.